-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 LkCozPXfTxrjnTPBi7aOjPP+ghykqxJ/nL2CzmR28ks/fYTOXqvxC62bCJ4E8HnK
 vnNuP+kcdHJ4voliAkFmdw==

<SEC-DOCUMENT>0000890163-10-000059.txt : 20100316
<SEC-HEADER>0000890163-10-000059.hdr.sgml : 20100316
<ACCEPTANCE-DATETIME>20100316151546
ACCESSION NUMBER:		0000890163-10-000059
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100316
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100316
DATE AS OF CHANGE:		20100316

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADEONA PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		10685265

	BUSINESS ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108
		BUSINESS PHONE:		734-332-7800

	MAIL ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19940606
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>s22-9619_8k.htm
<DESCRIPTION>ADEONA 8K
<TEXT>
<html>
<head>
    <title>s22-9619_8k.htm</title>
<!-- Licensed to: Starkey & Henricks-->
<!-- Document Created using EDGARizerAgent 5.1.6.0 -->
<!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="FIS_FORM"><!--EFPlaceholder--></a>&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">FORM 8-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CURRENT REPORT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to Section 13 or 15(d)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date of Report (Date of earliest event reported):&#160;&#160;March 10, 2010</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<a name="FIS_UNIDENTIFIED_TABLE"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ADEONA PHARMACEUTICALS INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nevada</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or other jurisdiction of incorporation)</font></div>
</td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1-12584</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Commission File No.)</font></div>
</td>
<td valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13-3808303</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(IRS Employer Identification No.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3930 Varsity Drive, Ann Arbor, Michigan 48108</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Address of principal executive offices)&#160;&#160;(Zip Code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Registrant&#8217;s telephone number, including area code:&#160;&#160;&#160;&#160;&#160;&#160;&#160;(734) 332-7800</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Former name or former address, if changed since last report)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><a name="eolPage2"><!--EFPlaceholder--></a><br>
</div>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_SECTION_1_BUSINESS_AND_OPERATIONS"><!--EFPlaceholder--></a><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="center" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="center" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(a)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(b)- (c)</font></div>
</td>
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr><tr>
<td valign="center" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="center" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(d)</font></div>
</td>
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On March 16, 2010, the Company announced the appointment of Jeff Riley, as director of the Board of Directors of the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As of the date of this report, Mr. Riley has not been named to any committee of the Board. Mr. Riley was not selected as a director pursuant to any arrangement or understanding with any other person, and does not have any reportable transactions under Item 404(a) of Regulation S-K.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">For his services as a director of the Company, Mr. Riley will receive the Company&#8217;s standard compensation applicable to nonemployee directors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
</tr><tr>
<td align="left" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(e) - (f)</font></div>
</td>
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 9.01.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a) &#8211; (c)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">N/A</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;Exhibits.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<a name="eolPage3"><!--EFPlaceholder--></a>The following exhibits are being filed as part of this Report.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="fis_unidentified_table_2"><!--efplaceholder--></a>Exhibit</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Number</font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="top" width="78%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="17%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="17%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Press Release dated March 16, 2010 regarding the appointment of Jeff Riley to the Board of Directors.*</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="17%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td colspan="3" valign="top" width="96%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* Filed herewith.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<a name="FIS_SIGNATURES"><!--EFPlaceholder--></a></font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 180pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">ADEONA PHARMACEUTICALS INC.</font></td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date:&#160;&#160;March 16, 2010&#160;</font></td>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By: <font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;/s/ James S. Kuo</font></font></td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:&#160;&#160;James S. Kuo</font></td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Its:&#160;&#160;Chairman, President and CEO</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="eolPage4"><!--EFPlaceholder--></a>&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_EXHIBIT_INDEX"><!--EFPlaceholder--></a><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT INDEX</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="fis_unidentified_table_3"><!--efplaceholder--></a>Exhibit</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Number</font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="top" width="78%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="17%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="17%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="17%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Press Release dated March 16, 2010 regarding the appointment of Jeff Riley to the Board of Directors.*</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="17%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td colspan="3" valign="top" width="96%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* Filed herewith.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
</body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>s22-9619_991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
    <title>s22-9619_991.htm</title>
<!-- Licensed to: Starkey & Henricks-->
<!-- Document Created using EDGARizerAgent 5.1.6.0 -->
<!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><a name="eolPage5"><!--EFPlaceholder--></a><a name="S22_9563_EXHIBIT101_HTM"><!--EFPlaceholder--></a><a name="FIS_EXHIBIT_10"><!--EFPlaceholder--></a><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT 99.1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><img src="s22-9619_alogo.jpg" alt="Adeona Logo"></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt">Adeona Appoints Jeff Lucero Riley as Board Director</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Ann Arbor, MI, March 16, 2010</font>, Adeona Pharmaceuticals, Inc., (AMEX:AEN - News), announced today that the appointment of Jeff Riley, M.B.A., as a new member of its board directors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Mr. Riley has more than 19 years of experience in the biotechnology and pharmaceutical industries during which he negotiated numerous worldwide strategic corporate alliances, established joint ventures, and assisted in obtaining venture financings to support product development. Currently, Mr. Riley is Managing Director of Black Crow Ventures, a life science-focused consulting firm with a commercial and transactional focus. He sits on the advisory boards of an Australia-based venture fund (Queensland Biocapital Fund) and Ruga Corporation, a Stanford University spin-out drug discovery company focused on endoplasmic reticulum stress targets.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Mr. Riley has held senior corporate and commercial development positions with biotech companies Amphora Discovery, Ontogen Corporation, and AvMax. In these positions, he was responsible for raising equity and negotiating alliances including in-licensing, out-licensing, distribution agreements, technology acquisitions and research agreements with large pharmaceutical companies and government agencies. Mr. Riley's pharmaceutical experience includes commercial management and mergers and acquisition roles for Pfizer and SmithKline Beecham. Additionally, Mr. Riley served as CFO and VP Corporate Development for Nichols Institute Diagnostics, a CLIA-certified molecular diagnostics and reference lab, later acquired by Quest Diagnostics. Prior to attending university, Mr. Riley served in the U.S. Army.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;The board is pleased at this exciting juncture to welcome an individual of Jeff&#8217;s background in the biotech and pharma industry,&#8221; stated James S. Kuo, M.D., M.B.A., Adeona&#8217;s Chairman and CEO. &#8220;We believe that Adeona&#8217;s portfolio of life science products will benefit from his transactional expertise and network as we seek to establish corporate partnerships and execute on our growth strategy.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Adeona Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Adeona (AMEX:AEN) is a pharmaceutical company focused on the diagnosis and treatment of central nervous systems diseases. In particular, the company has expertise on adult diseases characterized by zinc deficiency and chronic copper toxicity. A 16-center, double-blind, placebo-controlled, Phase 2/3 clinical trial of Adeona&#8217;s Trimesta <font style="DISPLAY: inline; FONT-SIZE: 10pt">TM</font> (estriol oral) is currently underway for the treatment of relapsing-remitting multiple sclerosis. In December of 2009, Adeona completed the first controlled clinical trial of oral zinc therapy for the dietary management of Alzheimer&#8217;s disease and mild cognitive impairment. The company is planning to launch Zinthionein <font style="DISPLAY: inline; FONT-SIZE: 10pt">TM</font> ZC GS0-150 as a prescription-only medical food. HartLab, an Adeon
a subsidiary, is a CLIA-certified clinical reference laboratory that exclusively offers the CopperProof Test Panel <font style="DISPLAY: inline; FONT-SIZE: 10pt">TM</font> , a diagnostic test that measures serum levels of free copper and zinc. For further information, please visit the company&#8217;s website at www.adeonapharma.com.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding designing additional clinical trials for its oral zinc therapies, dnaJP1, Zinthionein, Zinthionein ZC, flupirtine, or Trimesta. Adeona is at an early stage of development and may not ever have any products that generate significant revenue. Adeona's Hartlab subsidiary is generating modest revenues and
 its future success will likely depend upon its ability to successfully introduce and market new specialty diagnostic assays to generate additional revenues. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, a failure of Adeona's product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for the company's products or to comply with ongoing regulatory requirements, regulatory limitations relating to the company's ability to promote or commercialize its products for awareness, prevention, diagnosis or treatment of zinc deficiency and chronic copper toxicity, a lack of acceptance of Adeona's product candidates in the marketplace, a failure of the company to become or remain profitable, that we will continue to meet the continued listing requirements of the American Stock Exchange (which, unlike other exchanges, does not require us to maintain any minimum bid price with r
espect our stock but does require us to maintain a minimum of $6 million in stockholders' equity during the current year, for example), our inability to obtain the capital necessary to fund the company's research and development activities, a loss of any of the company's key scientists or management personnel, and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2008, Forms 10-Q for quarters ending in 2009 and any other filings with the SEC. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For Further Information Please Contact:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">James S. Kuo, M.D., M.B.A.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chairman, CEO and President</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(734) 332-7800 X36</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</div>
</body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>s22-9619_alogo.jpg
<DESCRIPTION>ADEONA LOGO
<TEXT>
begin 644 s22-9619_alogo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@`!`3$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8T+C`P`/_;`$,``@$!`0$!
M`@$!`0("`@("!`,"`@("!00$`P0&!08&!@4&!@8'"0@&!PD'!@8("P@)"@H*
M"@H&"`L,"PH,"0H*"O_;`$,!`@("`@("!0,#!0H'!@<*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_``!$(`*0`
M^@,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/WTHHHH`****`(YG\N>+G[[%<?AG^E254U=Q%'#-T*7*<^@)P?T
M)JW7+2JWQ-2F^EG\FK?FF4U[J84445U$A1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`9WBMRFA3LOW@A
MV^QP<5?BD6:)94/#*"/H:SO%9W:6(<9\R95Q^O\`(5+X9G-SX<L+@]7LXR?K
MM%?.T<5;BFKA^]*+^<9-/_TM&SC^X3\_Z_(O4445]$8A1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444$X&3
M0!B>,KD1FQM\XW3R.<>B0R'^>*?X`?S/!FG-_P!.P'Y<5D>.-05]<DA1LBQT
M*YF//&YQL6M/X;[O^$(T_=_SR/7_`'C7Y9E&9+&>)N)I1=U&G42^3PL7_P"3
MJ:^3.^I#EP,7YK_V[]+&Y1117ZF<`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%9NN7Y^U6V@V[?O;MB9,'[
MD*\NWMG[H]S[5<O[ZVTRREU"\E"10H6=CV`KA)->N8_#NJ>/[T;)]1/V734)
MYCBY''ZG_@-?"\:<48;):2PSE[SC*I4MO&A35YOR<W:E#KS3NOA9U8:A*J^;
MY+U>WW;OT*.L:J-0L?$OB)3E)YHK.V;U4-SC\%!_&NX\`QF+P9IRD?\`+LI_
M/G^M>:ZZO]E^`M)TL\27DKW<@]ONK^E>J^'K8V>@V5J1S':QJ?KM%?EOA+4Q
M.-XPQ%:O\<,-!S_QXFI+$OYKGY?+EMT._,%&.&26W,[>D4H_H7****_HP\8*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`**9<7$-K`]S<2!(XU+.['@`=37+7'CF:'PU>>,9%*1R.8=+@;^+L'/J2<
MGV"UX&=<295D/^]3L^2=1^5.FKRF_*[C%=7*22ZM:TJ-2K\/=+YLS?B-K5QX
MFU^V\`:/(<-,/M;+Z]<'V4<G_P"M67\0)4U7Q%8>!=&_U%EL@4+_`'S@$_@,
M?K3_```!HVD:E\1-4.^15:.V+]7D/4_B2!^=4_A[E=0U#QIJ7SK80-*6;^*5
M\@?UK^3\US/%<3SI?7'R5,UFJDU_SYP%!MQCY*7+.HVOBY$^I]#3IQH)\NJI
MJR\YO^DA/&C1ZSX\AT*S_P!3;/#90@=@"`?U)_*O7``H"J,`#@5Y!\,[676?
M'<-U.=QC9[B4GN?7_OHBO7Z_4_`GVF:4,USZ<>7ZS7LEVC!7BEY+GY5Z'!FM
MJ;IT5]E?G_PP4445^^'D!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`'(?&#59X=(MM`LV(DU"<*<=U!''XDBN:^)\Y
M6]T_P5IP)2Q@1-B_Q2,`!^F/^^C3UUA?$WB+PO/<2[C,[N03U(G<D?\`CHJ+
MPUY/B7XJSWTT@,<%Q+.Q)Z*APOZXK^/N+\VK\99C6IX=M+'UL+AX7^S1C3C6
MG]\ZL92]#Z+#0CAH)O["DWZWLOP0_P")=Q'HNFZ=X%LW&VUA$ESC^*0_Y)_$
M57UP?\(Y\/['0U^6?4Y#=7([[!]T?R_(U2B\SQUX]&6R+R\R?]F,?X**;X_U
MA=9\47$L)_<PGR8`.@1>./QR?QKX/.LZI5Z&:9U1TA4<<'AE_+2BES6]*481
M?_7YG92I-.G2?3WI>O3\?R.J^!NE8CO=:=>I6&,_JW_LM>@5C>`-(_L7PE9V
MC+AWC\V7_>;G],@?A6S7]A>&>1/AS@;`X.2M/D4Y?XI^^T_2]OD?.8ZK[?%3
METO^6@4445]V<@4444`%->:&,[9)54^A;%.K^7S_`(/'O$&O:7_P5<T"VTS6
M[RVC/P8TAC'!<NBY_M#4^<`]>*`/Z@P01D&BN)_9J=Y/V<_`#NQ9F\$Z422<
MDG['%7;4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`>!V
M]W/X9^*FF>'[@E3I_BF6U7/_`#RG`>#\\O\`E6=\-?%ALO#/C;Q.TIW6=BL"
M-GHTTC+_`$KJ?VGO"]WI$UG\4M&@+-:R0_;%4='AD\R&3ZG]Y#]9E]*\:DUN
M'1_AO\4+&"7A/$%@L;C^*)IIF4_3`!_&OY2S_(9\.Y_*"6E)8FI!_P"+"RC2
MM_A5**?FF=\<2W&SZV_.YW_PB\4C3O#_`(C^(%P^%TO3Q#;DG_EO*=J_Y]ZS
M/AQJL_C#QII_A])"PN+@>;_N#YF/Y`UR.I>(3X:_9;TD"3;+XC\1SSL<\M%`
MNS'TW8-=A^PQILGB'Q3JWBV<;H].M$@B)Z>9*221]%0C_@5?&9;PS#-L[R/(
M7&\%%5:B[NH_:S?SHQIQ^1T?7914YIZO^O\`,^FP`H"@<#I6/XW^(7@'X9:#
M)XI^)'CC1_#VF1'$NHZYJ<5I`GUDE95'YUL5^/7Q]_X-5=4_;6_;/\=_M#?M
MB?\`!0#QMK'A+5O$MQ=^#?#%@[7-[IMA*WF+:FYO&DC@2,DQK'%$1L13N!)`
M_N#8\@_2#0O^"C'_``3W\4:XOAGPU^W=\&M1U)W*)I]C\3])FG9@<$"-+@L3
MGC&*]CAFAN84N+>59(Y%#(Z-D,#R"".HK\<OB[_P9<?\$_\`7_`UW8_!;X^_
M$SPYXC\ECI^HZS>V>HV@EQ\OFP+;Q,R9Z[9%/OVKX\_X(&?M[_M:?\$RO^"I
M3_\`!(7]J/QG=:IX.U+Q;<>$1I-W?//!H>LAF%K<V#2<I!.X1#&-JLMPLFT,
MN"`?TI445_.Y_P`%F/\`@L;^V+_P4?\`V[4_X))?\$N_%6HZ9H;^(V\-ZCJW
MA^^:VN?$VHHS+=%KI#NAT^`))N*D!UBDD8LA50`?O+XQ_:M_9<^'FO2>%?'_
M`.TEX!T+5(CB73=8\8V5K<(?0QR2AA^5?S0?\'A/B?PUXQ_X*E>&O$7A'Q#8
MZKI]S\%-':WOM-NTGAE']H:GRKH2K#Z&OT._9G_X,SOV%O"?@&U?]J_XP^.?
M&_B^>`/JUQH.IQZ9IT4QY984\IY7`.1O=\MUVKG`_'__`(.#?^"<'P(_X)=_
MMVV7[.W[.NL>(;SP]J/@&QUX?\)+?1W%Q#-/=7D+1J\<<8*!;=",@G)/)XP`
M?UL_LT?\FX?#_P#[$C2O_2.*NVKB?V:/^3</A_\`]B1I7_I'%7XM?\'&/_!7
M#]J'XJ?M;Z5_P1A_X)S:]J-EK^JW]EI7C75]`NS!>:AJ-Z$,6E13J08(4CD1
MIY`P^\R,56.0,`?L'\2/V\_V&_@WXD?P;\7/VR_A5X7UB.0I+I7B'XA:;97,
M;#J&BFF5E_$5WW@'XD_#KXK^'(O&'PM\?:+XETB9B(=5T#58;RVD(ZA98693
M^!K\>/V<_P#@R^_8RT;X76B_M6?'OQ[XC\;75L'U6Z\)W]O8:?;3L,LD*2V\
MLDBJ<C>[`MC.U<[1\/\`[=7['G[8_P#P:Q_M:>#_`-I+]CCX]ZMKOPU\6WK1
M0QZH"D=Z\.'ETG58(R(IMT9+1S*%;&\J(VCR0#^H&BO-/V.?VH?`/[:G[+O@
M;]JCX9;TT;QOX?@U*WMI7#/:2,-LULY'!>*59(FQQNC-?E5_P=2?\%L/BE^R
M#;:3^P-^R1XRN-#\;>*=&&I>-?%&ES%+S2-.E=D@M;9U.8IYBDC,XPZ1A-N#
M*&`!^JOQ5_;0_8[^!.M_\(S\;_VL/AIX-U+C_B7^*_'>GZ=/R,C]W<3(W3GI
M76?#GXK?"[XQ>'E\7?"/XDZ!XITIVVKJ?AS6(+ZW+>@DA9ES^-?BM_P3O_X-
M!?@%XL^`FD_%K_@H]X^\:ZG\0O%=DFI:CX>T+6$M(M&:<"00S2O&\EQ<C=^\
M8L%#EE`;&]OE/_@J#_P3E_:9_P"#:/\`:`\'_MI?\$]OV@O$K>`?$.I_8=^I
M2AI+:[13+_9NHI&%AO;>:-9&1B@/[MP0K*CL`?TZ4C,J*6=@`!DDGI7@O_!,
MG]NWP5_P4B_8I\%?M:>#;)+&77[`Q:_HZR[_`.S-4A8Q75MGJ56124)P6C>-
MB!NQ7XR_\'J7QQ^,WA7XT_"7X-^%_BMXATWPGK'@B]O-8\-Z?K$T-E?SB\*"
M2>%&"2D*,#>#@9QU-`'[=^//V^?V%?A9?2:7\3?VT?A/X>NH6*RVFM_$33+6
M56&<J4DG#9X/&,UK_"']KO\`90_:"O#IWP&_:<^'OC6Y5"[6WA/QG8ZC(JCJ
M2EO*Y&.^1Q7XR?\`!,K_`(--OV#?VBOV+OAG^TS\>_C%\2-3U?X@^"=.\03Z
M=H=_:6%K8_:[=)A"FZWE=]N_&\M\V,[5SBO)O^"S?_!L'X5_X)\_L[ZC^W3^
MP)\;O&,D7@*6&^\0:#KUY&;VTMO,5/MMG=VR1,K1,RLR,N=NY@X*[6`/Z-Z*
M_*S_`(-8?^"L'Q:_X*$?LT>*?@K^TEXFEUSQW\*KFT1?$=VV;C5]*N5D$#SG
M^.:)X9(VD/+J8B<MN8_<G_!1W]FKXN?M>?L8>./V?/@-\<-2^'7B_P`06$2:
M'XMTS4)[5K25)XY"CR0?O!%(BM$^WG;(<4`=;\5_VMOV4_@->?V=\<OVF_A[
MX,N,`^1XL\:6.G/@]#MN)4/-2_"/]JK]E_\`:`GDM?@-^TAX"\;2Q(6EC\(^
M,++4F10<$D6\KX&>]?D_\%_^#+K]CC3M&.H_M._M3_$?QIXCNOWFH7F@M:Z9
M;&4\LP66.XE8DD_,TF3UP*^8?^"QO_!LMIW_``38^`M[^WW_`,$_?V@?&1C\
M`7$%[KFD:Q>(NI6$+2I$+VRO+5(F!B9U+(5R$+.'^7:0#^CNBOS@_P"#9K_@
MJ5\1O^"E7[$^IZ;\>M8_M+XA_##5X=(U[6&0!]5M)8B]G>28X\U@DT;D#YF@
MW]7-?H_0`4444`5M9TBPU_2KC1M4@$EO<Q&.5#Z'T]#W!]:^,OC-X0U+X9W/
MC[P)=ON2Y\/6.H64H&!*EM=1Q`CU(B<;O<-Z5]K5X_\`M@?#:#Q3X,A\76\(
M%QIJ36MW+_TY7,9AE)]HV9)O81&OA^/,@AG&42JP7[RFI6?]V47"?W1DVO3S
M)E=*Z/EOXTZ\;3X+?"S3(WPAT2]N2,]6>Z;)_P#':^FOV"/#W]E?`.#7)$Q)
MK.HSW))'.Q2(E'T_=D_C7QO\8-2FN/@G\-+J=2LEI::IIUP&&"DD5X7VGW"R
MK7WY^S;I":'\`O!^GHFW'AZUD8?[3QAR?S8FOS3PXP$:_&]7%R7\/#44O)NE
M27X)-$PFY.QVU?/?[=?_``5,_88_X)P>'H=8_:P^.NG:'?7D)ETSPU:*UWJM
M\N2-T5K$#)LR"/,8+'D8+"NZ_;(_:"L_V3_V3/B3^TS?:>+Q?`?@?4]=CLBV
M/M4EM;22QPY[;W54S_M5_.5_P;V_L:6W_!;S_@HS\2_VO/\`@H)J<_CVQ\&Q
M6NL:[I>J2LT.K:I>RRK9P2KG`M(H[:X(@&%Q'$F-FY3_`$&:'WZ/^#K'Q;\?
MM6N-(_X)U_\`!)?XQ?%N.*4Q+J<J-;0AO5Q9V]V$'^\ZGZ5^1^I?%KXV_&W_
M`(..O!WQ<_:%^"4WPU\;:W\>_"EQKO@F:=GDTF3SK%5C9F"L28U1SD`_/T%?
MUQ>%?"?A;P+X=L_"/@GPU8:/I.GP"&PTS2[-+>WMHQT2..,!44>@`%?RU_MR
M?\K:R_\`9Q/A#^6F4`?TA?\`!0SXVZI^S=^PC\8?CSH-WY&I>%/AMK.HZ5-N
MQLNX[.4P'/\`UUV5^!'_``9;?!+1?'O[=7Q-^/WB"V6ZO/!/@%+;399AN:&Y
MU&YVM,">C^5;S)GTE;UK]S/^"OG@'5?B?_P2W_:`\$Z'#)+>77PFUM[>*(9:
M1HK228(!W)\O&.^:_%+_`(,D/B)HFD_M2?&WX5W5PBW^N^!-.U.SC)&7CL[Q
MXY,>N#>QT`?T=5_+A_P>6_\`*6+0/^R+:/\`^G#4Z_J/K^7#_@\M_P"4L6@?
M]D6T?_TX:G0!_2Q^S2RK^S?X`9F``\$:422>G^AQ5_-;_P`&_'CGP=^T3_P<
M*^,_VL?C=XHT^S6T3Q?XR74=;O8X(8KBYN/LZDO*0%VI?-@9XVC'`K^E#]FZ
M&.X_9K\`P3+E'\#:4K#/4&SB!K^2O_@EA^P3^S[^TE_P6-D_8(_;,FURTTJ7
M7/$.DM'HVI+93MJ=CY[I$SLCX5OL\BE0`Q)&"*`/Z=_BM_P63_X)5_!4R)\0
M?V_?A=#+#D2VVF>*H-1F4CJ#':&5\^V,U^1'_!RE_P`%KO\`@F)_P4`_88C_
M`&<_V:OBMJ/BSQ?IWCC3]8TVYC\+WEK:QQQ)/%,?-N8X^J3$``')QZ5^C/PM
M_P"#9C_@BS\+/+FB_8\M]?N(Q@7'BGQ+J-]N]S&TXB/_`'Q7TE\+/^">?[!G
MP1\I_A%^QA\+?#LL)!2ZTKP)813Y'0F41;R?<DF@#X;_`.#0CQOKOBK_`()`
MV>@ZT)O*\.?$76K#36ES@V[^3=?+GMYEQ+7Y!?M87Z_MD?\`!T[=>&_&C_;-
M/N?VE=*\.S03`,CV.G7EO9F+!XVM';$?\"-?U@6]O;VD*V]K`D<:*`D<:@*H
M'8`=*_DY^)]D/V=O^#JV:?QCF"WB_:OM+\R3#:%M[_5(YXG.>WEW*'/3'-`'
M]9(``P!7Y]?\'1/PVTKXA_\`!%;XJWFHVJR3>&[C1]8L)"!F&6/4K>(L,],Q
MS2+]'-?H+7P9_P`'-/B_3?"/_!$[XT#4;A$.J6NDZ?;!CR\LFK6>%'OA2?H#
M0!\9_P#!DC\5]6UG]FKXV?!6\N6:T\/^---U>QC+<(U[:R12X';_`(\D/XU\
M_P#_``>W_P#)V?P4_P"R=7W_`*7FO:_^#(3P%JEE\'?CY\3[BW*V>H^)=%TR
MUE(.'DM[>YEE'IP+F+_OJO%/^#V__D[/X*?]DZOO_2\T`?M9_P`$</\`E$]^
MSA_V17PW_P"FZ&J/_!;$`_\`!(_]HO(_YI'K7_I,]7O^".'_`"B>_9P_[(KX
M;_\`3=#5'_@MA_RB/_:+_P"R1ZU_Z3/0!^.'_!D03_PT=\=AGC_A"=)X_P"W
MR6OZ+I)(X8VFFD5$1269C@`#J2:_G0_X,B/^3C_CM_V)&D_^EDM?3W_!X?\`
M\%!/BA^SC^S/X(_9$^$'B:YT>X^+4]_+XMU"QF,<[:1:"%3:!@<JD\DX#XQE
M(2ARLC`@'T!^VK_P<_?\$MOV/?$=W\/-%\?:K\4O%-G,8)](^&]FEW#%,#M\
MMKR1T@)SP1&\A!XQGBOB[_@H!_P73_;\_;._82^*_@GP'_P18^(?AKX;Z_X$
MU"WUOXB^++JZ2+3[!X6WW85K*.-MB_-Q*PR*^H/^#:O_`()$?LX_LN_L1^`?
MVN/%OPWTO7/BO\1="A\02>)M5LTGFT>SN5\RVM;3>#]GQ"R,[KAW=V!8JJJ/
MJ3_@M=_RB0_:+_[)%K7_`*2O0!^3O_!CC-*-5_:7MQ(=C6_A%BF>"0VL@']3
M^=?T!5_/W_P8Y?\`(:_:6_Z]?"/_`*%K%?T"4`%%%%`!4.HZ?9:MI\^EZE;)
M-;W,+17$,@RKHP(93[$$BIJ*32DK,#\\OVJ_AIJ'P_T'Q%X'N5=QH/B>/6-/
MF?K-9WL?DRR9[GSH8-V.`TN*^Y?@A=17OP8\)74``1_#5B5"]!_HZ<5QO[67
MP4M_BAX+FU6TMP;RUL)[6ZVKDS6<@!8>K&*18[A1W:':/O4_]B?Q'/KO[..@
MZ=J(VWVAK+I-_$3DQR6\AC`/_``A_&OSK(<H61<8UZ:7N5:=XO\`P2V^2FHI
M=HW,(1Y*K0[]N;]GJ?\`:R_8T^*?[,]E?I:77CKP%JNBV%W*?D@N9[61(9&_
MV5D*,?8&OYO/^#>K_@H5X?\`^"(_[<_Q._9O_;Z\-:IX+TOQ?'::3XFO+O3Y
M'DT'5+"68V\DT:`LUNR75P"Z!OOQN,IDU_4Q7@O[8?\`P3!_8'_;Y2*;]K+]
MF'PWXLO[>$16VN20O:ZE#&.0BWELT<^P$DA-^W)/'-?HQN9\'_!77_@EO<>'
M1XJB_P""A'P>^Q-!YP9OB!8+)MQG_5F7>#[;<^U?S<?'#XZ?"?\`:6_X.@-&
M^.'P-\:6WB+PIKW[0OA231]:LT=8KM(Y=/A9TWJI*[XW`..<9&00:_;"/_@U
M`_X(KQZE_:!^`?B1D\PM]E;Q_J7E8_N_ZW=C\<^]?27[*/\`P2)_X)L?L2:O
M!XG_`&:OV0/".@ZW;#_1_$5S:OJ&I0YZF.[O&EFCSWV,H_"@#Z)U#3['5K"?
M2]3LX[BVN86BN+>9`R2QL"&5@>"""01[U_*Q^TA\"/VF/^#8O_@KWI7[2'PY
M\&7FJ_#276[F7PC>R%Q::WH-SD7&D33`$)<Q1MM^;G?%%,%(P*_JMKF?B_\`
M!?X1?M`^`;[X6?'+X9Z%XN\-ZD@6^T/Q%I<5W;38Y!,<BD;@>0PY4\@@C-`'
MQY^S_P#\'(7_``1]^/'P]M/&UQ^UUHO@N\E@5K[PYXX22PO;*3&3&VY3'+@\
M;HG=3ZU^!?\`P=`?MD_LU_MO_P#!22Q^*G[*_P`4K3QAX<TOX:Z;HUSK-A;S
M)";R*[OI9$0RHI<!9X_G4%3DX)P:_<SQM_P:N_\`!%7QIKLNNQ?LT:KHWG,6
M:ST3QOJ<,`).3M1IFVCV&`.P%>F_LX_\$!_^"1?[+6OV_B[X9_L6>&KO6+20
M26VI^+);C6I(G'W71;Z26.-P>0RJ"#R#0!]'?LT?\FX?#_\`[$C2O_2.*OY[
M?^#DK_@G+^T-_P`$_P#]O^T_X*^_LC:9>Q>'-8\36GB'4M5TRV,@\,^)(I$9
MI)U`.(+F11)N;Y6DDEC;&Y`W](ZJJ*$10%`P`!P!5;6]#T7Q-H]UX=\2:/:Z
MAI]]`\%[8WUNLL-Q$PPT;HP*NI!(((((-`'Y;_L0?\':O_!-?X[?"_3Y_P!J
MOQ==_"3QM#:HNMZ=?Z-=WFG33@8:2UGMHY3Y;'D+*%=<X^;&X];\?_\`@ZW_
M`."//P;\-3ZGX&^,NM_$;4UB)M='\(^%[M&E?'`::\2"-!GJ2Q(]#79?&K_@
MV>_X(R?&_P`23>+-3_9&M_#UY<R&2X7P9KU[I=NQ))XMX91#&.>B(HJQ\%_^
M#:W_`((Q?!'6(/$&D_L;:=X@O+=@T3^,]:O=6BR#GYK>XF:!_P#@49H`^M/V
M:_CYX&_:F_9^\&_M&_#2Y\W0O&WARTUC3=S@M&D\2N8GQQO0DHP[,I':OPC_
M`.#O/_@F+\3?#GQGTC_@JK\"-!O)],N;&ST_XC3:7$QETF_M<)9ZDQ7E8WB$
M4)?HCV\>3^\&/Z!O#OASP]X0T*T\+>$M!LM+TS3[=8+#3M.M4@@MHE&%CCC0
M!44#@```5+JVDZ5K^EW.AZ[IEO>V5Y`T-W9W<*R13QL"&1T8$,I!(((P0:`/
MR]_X)Q?\'3'_``3S^/O[/.AO^U]\9[/X9?$K3=,C@\4V&M6%Q]COKB-`'NK6
M:*-T*2$;Q$Q#H6*X8`,WYZ?\'%G_``6L\%?\%7=1\%?\$]O^"=NFZYXPT$^)
MXKS4M4M-*FCD\2:IAHK2TM('42M$GF2,6=5WN4P`(]S?JU\:/^#8[_@C)\:_
M%<_C*^_94_X1R[NIC+<P^#?$5[IMJ[$Y.VVCD\F(=ML:(/0"O9_V*O\`@D)_
MP3I_X)\:DWB3]EG]F31=$UZ2$Q2>*+Z6;4-3V$894N;IY'A5A]Y8RBMCD&@#
MG/\`@B%_P3QN/^"9O_!/'PA^SUXG$#>+[QI==\=S6[!D_M6ZVEX58?>$,:Q0
M!APWD[AC=BOQW_X/;_\`D[/X*?\`9.K[_P!+S7]']>!_M??\$O/V"_V]_$^D
M>,OVN_V<],\;:GH-@]EI%W?ZC>0FV@=][(!;S1@@MSD@F@#(_P"".'_*)[]G
M#_LBOAS_`--T-4?^"V'_`"B/_:+_`.R1ZU_Z3/7T#\*/A9X`^!WPRT#X.?"K
MPW%H_AGPOI%OI>@Z5!([I9VD$8CBB5I&9B%10,L2>.2:9\7OA)\.OCU\+]>^
M"_Q<\,1:UX8\3Z7-IVO:3/*Z)=VLJE9(F:-E8`@D94@^]`'\^/\`P9$?\G'_
M`!V_[$C2?_2R6OH3_@\O_8:^*/QI^`?PZ_;%^&/ARZU:U^&4VH6'C*VLH3))
M:Z?>&!H[PJ.?*CEA*NW\/G*QPJL1^FG['_\`P3$_80_8&U_6O%'[(7[.VF>"
M;_Q#9Q6NLW-AJ%Y,;J&-RZ(1<32``,2>`#S7NMW:6M_:R6-];1S0S1E)H94#
M*ZD8*D'@@C@@T`?D;_P0*_X+_?L)>+?V&_`'[,G[2OQTT+X<>/\`X=^'[?P_
M+%XMO%LK/5;6V016]S!<R8BR8E0.C,K!U8@%2"?5?^"T7_!5C_@FYJ__``3,
M^-/PO\+_`+;7PXUWQ%XL^'6IZ7X>T7PWXH@U*XO+N:!DCC"6K2%<L1\S84=2
M0*[_`./W_!N)_P`$<?VB?$=SXP\4?L=Z9H>IWDADN;GP7JMWH\;L3DG[/:RK
M`"3G)$8)S7*^!/\`@UH_X(I^!]3359OV7+_6VCD#I#KOC;5)HLCU19U##V;(
M/>@#X'_X,<O^0U^TM_UZ^$?_`$+6*_H$KB/@-^S7^SY^RWX+7X=_LX_!7PQX
M'T0,'?3?#&BPV<<K@8\R3RU!D?'5WRQ[FNWH`****`"BBB@`(!&".#7F'@OP
MVGP<^,^I:):)Y>@^,Q]LL%`PEOJ,28DB]O,A"L/^N!ZDUZ?6;XK\-6OBK1WT
MR:4Q2JZS6ET@^:WF0ADD7W#`''<9!X)KCQ>&59PJ1^.#O'[K-?--KRT?0F2O
MJ:5%4]$OKJ\L@FI1I'>0@)=QQDE0^.2I/53U'L>><@7*ZXR4E=%!1113`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@"K=1K%>0W48VNS^6Y'\2X)P?H>GX^IJU114QW8@HHHJAA1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
